ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 22 for:    gene therapy | Sickle Cell Disease

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02193191
Recruitment Status : Recruiting
First Posted : July 17, 2014
Last Update Posted : April 11, 2018
Sponsor:
Collaborators:
Sanofi
New York Blood Center
Weill Medical College of Cornell University
Duke University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:
The purpose of this research study is to test the safety and efficacy of a drug called Plerixafor. Plerixafor is approved by the US FDA for use in increasing blood stem cell counts before collection in cancer patients. It is not yet approved for patients with sickle cell disease. The investigators want to find out if Plerixafor can be used to increase cell counts in patients with sickle cell disease.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: Plerixafor Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Actual Study Start Date : September 2014
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Plerixafor

Arm Intervention/treatment
Experimental: Plerixafor
Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
Drug: Plerixafor



Primary Outcome Measures :
  1. safety [ Time Frame: up to 30 days ]
    Safety is assessed using a dose limiting toxicity (DLT) endpoint. Definition of a DLT is the occurrence of any of the below events that meets the following criteria: The occurrence of a vasoocclusive crisis requiring hospitalization, acute chest syndrome, CNS acute event, or any other disease related ischemic-based adverse event (AE) should be considered as a DLT, if occurring in the 48 hours DLT observation period.

  2. efficacy [ Time Frame: ≥ 30/ul at either 6-12 hours or 24-48 hours post plerixafor. ]
    Efficacy is defined as 100% of evaluable patients reaching a PB CD34 concentration ≥ 30/uL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have confirmed and measurable Sickle Cell Disease, defined by SS or Sβ thalassemia confirmed by hemoglobin fractionation.
  • ≥ 18 to 65 years of age
  • Patient must have a ECOG performance status ≤2 or Karnofsky score > 70%
  • Patients must have acceptable organ and marrow function as defined below:

    • WBC ≥ 3,000/μL
    • ANC ≥ 1,500/μL
    • platelets ≥150,000//μL
    • Hemoglobin ≥ 6 gm/dL
    • Calculated creatinine clearance ≥ 60ml/min * *Using the Cockcroft-gault equation [140 - Age(yrs)] [Weight(kg)] x 0.85 if Female 72 [Serum Creatinine (mg/dL]
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Each patient must be willing to participate as a research subject and must sign an informed consent form.

Exclusion Criteria:

  • Patients who are:

    • Receiving or received treatment with an investigational agent within 4 weeks prior to entering the study OR
    • have not recovered from adverse events due to agents administered more than 4 weeks earlier as determined by the treating physician.
  • Patients with ALT(SGPT) > 2.5 X upper limit of normal
  • Patients with a creatinine clearance of < 60 ml/min
  • Patients who have uncontrolled illness including, but not limited to:

    • Ongoing or active infection
    • Emergency room admission or hospitalization in the past 14 days
    • Major surgery in the past 30 days
    • Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.
  • Female patients who are pregnant or breast-feeding
  • Patients with active hepatitis B, hepatitis C, or HIV infection
  • Patients with poor cardiac function as defined by an ejection fraction < 40% are excluded due to potential poor tolerance of the fluid shifts with leukapheresis (only for patients enrolled on second phase of protocol for Leukapheresis).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02193191


Contacts
Contact: Farid Boulad, MD 212- 639-6684
Contact: Susan Prockop, MD 212-639-6715

Locations
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Farid Boulad, MD    212-639-6684      
Contact: Susan Prockop, MD    212-639-6715      
Principal Investigator: Farid Boulad, MD         
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
Contact: Tsiporah Shore, MD    212-746-2646      
United States, North Carolina
Duke University Not yet recruiting
Durham, North Carolina, United States, 27708
Contact: Jen-Tsan Chi, MD, PhD    919-668-4759      
Principal Investigator: Jen-Tsan Chi, MD,PhD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Sanofi
New York Blood Center
Weill Medical College of Cornell University
Duke University
Investigators
Principal Investigator: Farid Boulad, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT02193191     History of Changes
Other Study ID Numbers: 13-229
First Posted: July 17, 2014    Key Record Dates
Last Update Posted: April 11, 2018
Last Verified: April 2018

Keywords provided by Memorial Sloan Kettering Cancer Center:
Plerixafor
13-229

Additional relevant MeSH terms:
Anemia, Sickle Cell
Hematologic Diseases
Genetic Diseases, Inborn
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hemoglobinopathies
JM 3100
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents